Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
SAN DIEGO , July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the publication 1 of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure in the vein flowing into
View HTML
Toggle Summary Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates
SAN DIEGO , May 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2018 , and provided updates on its
View HTML
Toggle Summary Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension
SAN DIEGO , April 30, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor.
View HTML
Toggle Summary Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results
SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2018 , after the market close on Wednesday, May 2, 2018 . Conatus will host a conference call and audio webcast at
View HTML
Toggle Summary Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
SAN DIEGO , April 18, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the publication 1 of results from both in vitro and in vivo studies of its
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Pan-caspase Inhibitor IDN-7314 Reduces Inflammation and Liver Injury in Mouse Model of PSC SAN DIEGO , April 09, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced an
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Biopsy-based Proof of Concept in Liver Fibrosis and Cirrhosis Supports Further Evaluation   Conference Call and Webcast Presentation at 4:30 p.m. ET Today  SAN DIEGO , April 04, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates
SAN DIEGO , March 07, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31,
View HTML
Toggle Summary Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- At three upcoming investor conferences in March, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) President, Chief Executive Officer and co-founder, Steven J. Mento , Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2017 , after the market close on Wednesday, March 7, 2018 .
View HTML